Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2049-9957
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon ; volume:3 ; number:1 ; day:30 ; month:1 ; year:2014 ; pages:1-11 ; date:01.2014
Infectious diseases of poverty ; 3, Heft 1 (30.1.2014), 1-11, 01.2014
- Urheber
-
Meriki, Henry D.
Tufon, Kukwah A.
Afegenwi, Mbunkah H.
Nyindem, Bernard A.
Atanga, Pascal N.
Anong, Damian N.
Cho-Ngwa, Fidelis
Nkuo-Akenji, Theresa
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/2049-9957-3-5
- URN
-
urn:nbn:de:101:1-2021082910134660131216
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meriki, Henry D.
- Tufon, Kukwah A.
- Afegenwi, Mbunkah H.
- Nyindem, Bernard A.
- Atanga, Pascal N.
- Anong, Damian N.
- Cho-Ngwa, Fidelis
- Nkuo-Akenji, Theresa
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study
Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Nachbetreuung von PatientInnen mit „sustained virologic response“
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa
Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study
Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Nachbetreuung von PatientInnen mit „sustained virologic response“
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa
Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda
Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study
Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Nachbetreuung von PatientInnen mit „sustained virologic response“